Recent preclinical studies have shown the feasibility of specific variants of nuclear transfer to prevent mitochondrial DNA disorders. Nuclear transfer could be a valuable reproductive option for carriers of mitochondrial mutations. A clinical application of nuclear transfer, however, would entail germ-line modification, more specifically a germ-line modification of the mitochondrial genome. One of the most prominent objections against germ-line modification is the fear that it would become possible to alter ‘essential characteristics’ of a future person, thereby possibly violating the child's right to an open future. As only the nuclear DNA would contain the ingredients for individual characteristics, modification of the mtDNA is often considered less controversial than modification of the nuclear DNA. This paper discusses the tenability of this dichotomy. After having clarified the concept of germ-line modification, it argues that modification of the mtDNA is not substantively different from modification of the nuclear DNA in terms of its effects on the identity of the future person. Subsequently the paper assesses how this conclusion affects the moral evaluation of nuclear transfer to prevent mtDNA disorders. It concludes that the moral acceptability of germ-line modification does not depend on whether it alters the identity of the future child—all germ-line modifications do—but on whether it safeguards the child's right to an open future. If nuclear transfer to prevent mtDNA disorders becomes safe and effective, then dismissing it because it involves germ-line modification is unjustified.
- Embryos and fetuses
- gene therapy/transfer
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding This work was supported by a grant from the Ter Meulen Fund, Royal Netherlands Academy of Arts and Sciences, The Netherlands and by GROW, School for Oncology and Developmental Biology, Maastricht University.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Ethics of mitochondrial gene replacement: from bench to bedside
- De novo mtDNA point mutations are common and have a low recurrence risk
- Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta
- Should mitochondrial replacement therapy be funded by the National Health Service?
- Preimplantation genetic diagnosis for mitochondrial DNA mutations: analysis of one blastomere suffices
- Lesbian motherhood and mitochondrial replacement techniques: reproductive freedom and genetic kinship
- Analysis of mtDNA variant segregation during early human embryonic development: a tool for successful NARP preimplantation diagnosis
- Mitochondrial donation and ‘the right to know’
- Clinical mitochondrial genetics